Eversept Partners, LP Madrigal Pharmaceuticals, Inc. Transaction History

Eversept Partners, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$94.77 - $215.54 $890,838 - $2.03 Million	-9,400 Closed	0 $0
Q3 2018 Nov 08, 2023	BUY	$207.3 - $300.31 $1.02 Million - $1.47 Million	4,900 Added 108.89%	9,400 $2.01 Million
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $1.02 Million - $1.47 Million	4,900 Added 108.89%	9,400 $2.01 Million
Q2 2018 Nov 08, 2023	BUY	$101.55 - $313.9 $456,975 - $1.41 Million	4,500 New	4,500 $1.26 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $456,975 - $1.41 Million	4,500 New	4,500 $1.26 Million

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.35B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.